- mail us help@24marketresearch.com
- Int'l 1(332) 2424 294 (Int'l)
TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Moexipril is an angiotensin-converting enzyme (ACE) inhibitor that plays a critical role in the treatment of hypertension (high blood pressure) and congestive heart failure. It works by inhibiting the enzyme that constricts blood vessels, thereby relaxing them and improving blood flow. By managing blood pressure and heart function, Moexipril helps reduce the risk of stroke, heart attack, and kidney problems. The global Moexipril market includes the manufacturing, distribution, and sale of this drug, catering to individuals suffering from cardiovascular diseases.
The global Moexipril market size was valued at USD 102 million in 2024 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.40%, reaching USD 133.28 million by 2032.
This growth is driven by the increasing prevalence of hypertension and heart disease worldwide, coupled with rising awareness and the expanding healthcare infrastructure. The market's growth trajectory is also bolstered by the development of generic versions of Moexipril, which have made the drug more accessible to a wider population.
Drivers:
Rising Cardiovascular Diseases: The increasing incidence of hypertension and heart failure globally is a significant driver. According to the World Health Organization (WHO), nearly 1.13 billion people suffer from hypertension, a key condition treated with Moexipril.
Aging Population: The growing elderly population is more prone to heart disease and high blood pressure, further fueling demand for medications like Moexipril.
Increasing Healthcare Access: With the expanding reach of healthcare services, more patients have access to treatments for chronic conditions, contributing to the demand for Moexipril.
Restraints:
Side Effects and Adverse Reactions: Like many other ACE inhibitors, Moexipril can have side effects such as dizziness, cough, and high potassium levels, which may limit its use in some patients.
Competition from Generic Drugs: While generic versions of Moexipril provide a cost-effective alternative, they also pose a threat to the profitability of branded versions.
Opportunities:
Expanding Market in Developing Regions: As healthcare improves in developing nations, there is an opportunity for Moexipril to gain a foothold in these untapped markets.
Research and Development: Ongoing research may lead to new formulations or combination therapies that could expand Moexipril’s use beyond hypertension and heart failure.
Challenges:
Regulatory Hurdles: The approval process for new drugs or formulations can be time-consuming and costly, presenting a challenge for companies in the market.
Generic Substitution Pressure: The shift towards generic drugs may create pricing pressures for branded Moexipril.
The global Moexipril market is characterized by varied demand across different regions.
North America:
The North American market, particularly the USA, holds a significant share, with a market size of USD 28.15 million in 2024. The region is projected to grow at a CAGR of 2.91% from 2025 to 2032. High healthcare expenditure, increasing awareness about cardiovascular diseases, and the presence of major pharmaceutical companies like Pfizer and Teva Pharmaceuticals contribute to the dominance of this region.
Europe:
Europe is another key player in the global Moexipril market. Countries such as Germany, the UK, and France have a high prevalence of hypertension and heart failure, driving demand for Moexipril. The region is experiencing a steady growth rate due to the aging population and increasing healthcare initiatives.
Asia-Pacific:
The Asia-Pacific region is expected to witness the fastest growth in the coming years. Countries like China and India, with their large population bases and rising rates of hypertension, are the primary contributors to the market’s expansion. Additionally, growing healthcare access in these regions is a key factor driving the uptake of Moexipril.
South America and Middle East & Africa:
These regions have lower market shares but are growing steadily, especially with the increasing awareness of cardiovascular diseases and expanding healthcare systems. The demand for affordable medications and the rising healthcare infrastructure offer significant opportunities in these regions.
Several global pharmaceutical companies are competing in the Moexipril market, including:
Pfizer: A major player, Pfizer has established a strong market presence with its branded formulations of Moexipril.
Shermco: Known for its affordable generic versions of ACE inhibitors, including Moexipril.
Teva Pharmaceuticals: A leading generics manufacturer, Teva plays a significant role in Moexipril's distribution.
Viatris, UCB Pharma, Glenmark Pharmaceuticals: These companies are key competitors in the market, focusing on both branded and generic versions of the drug.
These companies continually innovate, expanding their product offerings and improving their market positioning to meet the growing demand.
This report provides a deep insight into the global Moexipril market, covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and assessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Moexipril Market. This report introduces in detail the market share, market performance, product situation, operation situation, etc., of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Moexipril market in any manner.
Hypertension: The majority of Moexipril's usage is in treating hypertension. The drug is effective in lowering blood pressure, which is crucial in preventing strokes, heart attacks, and kidney failure.
Heart Failure: Moexipril is also used in the treatment of heart failure, where it helps improve heart function and reduce the symptoms of the condition.
7.5mg
12.5mg
15mg
Other
Pfizer
Shermco
Avet Pharmaceuticals
Chartwell Pharmaceuticals
Glenmark Pharmaceuticals
Viatris
Teva Pharmaceuticals
UCB Pharm
Emcure Pharmaceuticals
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
What is the current market size of the Moexipril market?
Which are the key companies operating in the Moexipril market?
What are the key growth drivers in the Moexipril market?
Which regions dominate the Moexipril market?
What are the emerging trends in the Moexipril market?